Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story deserves a closer look.
The Moderna Story Has Not Changed
Strip away the bounce and the fundamentals tell the same story long-term investors have heard for three years running. Full-year 2025 revenue collapsed to $1.94 billion, a roughly 40% drop, and management’s own 2026 guidance calls for up to 10% growth off that depressed base. Roughly 80% of Q1 2026 sales came from outside the U.S., and the entire franchise is still effectively a single COVID product.
Meanwhile, cash is bleeding. Year-end cash is projected to fall from $8.1 billion at the end of 2025 to $4.5 billion to $5.0 billion by year-end 2026. Management drew $600 million on a credit facility. Q1 GAAP net loss widened to $1.34 billion. There is no dividend, no buyback, and the upcoming catalysts (the August 5, 2026 flu vaccine PDUFA, melanoma readouts, norovirus Phase 3) are binary catalysts rather than earnings drivers. Polymarket traders priced a 100% implied probability of the Q1 miss before resolution. That is what a crowded headline trade looks like.
The Gilead Alternative
The smarter rotation is into Gilead Sciences (NASDAQ:GILD), which trades at a forward earnings multiple of 15 with a 2.46% dividend yield and a market cap near $162 billion. Three reasons this is the better long-term holding for a retirement portfolio.
1. A cash-flow machine generating real free cash flow. The HIV franchise grew 10% to $5.03 billion in Q1 2026, with Biktarvy alone bringing in $3.36 billion for the quarter. Patent protection on Biktarvy was extended to April 2036, meaning no major loss of exclusivity for a full decade. Non-GAAP product gross margin expanded 200 basis points to 87.5%, and Q1 free cash flow hit $2.427 billion, up 237.08% year over year.
2. Real shareholder returns. Gilead declared a $0.82 quarterly dividend payable June 29, 2026, repurchased $419 million of stock in Q1 alone, and has a $6.0 billion buyback authorization. Moderna returns no capital to shareholders and is drawing on its credit facility.
3. Pipeline optionality funded by the business. The headline 2026 EPS loss guidance is entirely an artifact of roughly $11.5 billion in one-time IPR&D charges from the Arcellx, Ouro Medicines, and Tubulis acquisitions. Operations are fine. CEO Daniel O’Day described the setup as “the strongest pipeline in Gilead’s history… With up to four potential launches and five Phase 3 updates anticipated in 2026.” That includes a BIC/LEN PDUFA on August 27, 2026 and anito-cel for multiple myeloma on December 23, 2026. Gilead can pay for all of it from operating cash flow.
The Action
Moderna’s chart looks exciting because the prior year was a disaster. Gilead, up 22.98% over the past year with a beta of 0.332, has been doing the quiet compounding retirement portfolios actually need. The cash-flow story warrants closer research attention than the headline bounce.
Top Gaining Stocks
Top Losing Stocks